Kornimate/medical-research-clean huggingface dataset:
role of the microparticles and of tissue factor in the pro-thrombotic phenotype and the thromboembolic complications during the acute lymphoblastic leukemia in children.

Conditions: Acute Lymphoblastic Leukemia

Summary: acute lymphoblastic leukemia is the most common malignancy of the child. current therapeutic strategies allow healing of over 80% of children. however these treatments are associated with toxicity, with a mortality of 1-2%. the most frequent complications, occuring during treatment initiation, are the thromboembolic complications. the most commonly accepted explanation is that of an anti-thrombin depletion by chemotherapy used in the treatment, l-asparaginase. but the anti-thrombin supplementation showed no efficacy in the prevention of these thromboembolic complications. therefore most authors consider that a multifactorial mechanism is behind these events, involving both treatment and malignant cells. the interaction of these two factors participate in the damage of the vascular endothelium. the microparticles are membrane fragments derived from budding from the membrane of activated cells or apoptosis. their thrombogenic role is linked to the expression of coagulation activators such as tissue factor. it is also associated with their role in the modulation of signaling pathways involved in the invasiveness and angiogenesis in endothelial cells. in acute lymphoblastic leukemia, the presence and role of microparticles have not been studied. our hypothesis is that of production of microparticles upon lysis of blasts then upon activation of endothelial cells induced by the induction therapy, participating in a procoagulant phenotype.

the aims of this study are * quantify the microparticles in children receiving induction therapy for acute lymphoblastic leukemia at diagnosis and during treatment * study the origin of these particles and the expression and activity of the tissue factor on their surface, at diagnosis and during treatment

Eligibility criteria:
inclusion criteria: * children with acute lymphoblastic leukemia * children and their parents consenting to participate to the study * children enrolled in the national healthcare insurance program
liver transplant does it affect the brain

Conditions: Brain Damage; Postoperative Cognitive Dysfunction; Neuron Specific Enolase; Glial Fibrillary Acidic Protein

Summary: neuronal damage caused by neuroinflammation in patients undergoing major surgery is the most determinant factor of postoperative cognitive disfunction (pocd). neuronal damage can be detected through the measurement of biochemical markers of brain damage. the aim of this study was to evaluate neuronal damage and its association with pocd during liver transplantations. after the approval of the ethics committee and patient consents, preoperative and postoperative cognitive functions of 33 patients undergoing liver transplantation (ltx) were measured using the mini mental test (mmt) whereas simultaneous neuronal damage was evaluated through the measurement of s-100 beta (s100β), neuron specific enolase (nse) and glial fibrillary acidic protein (gfap) levels. as a result, there was no statistically significant difference between preoperative and postoperative mmts. however, there was a statistically significant decrease in postoperative gfap and a statistically significant increase in nse compared to preoperative values. the decrease in s100β level was statistically insignificant. in conclusion, neuroprotective approaches in the investigator's anesthesia protocol protect patients from brain damage during liver transplantation and prevent the development of pocd, which was indicated by the insignificant change in mmt scores and s100β level and the significant decrease in gfap. since the significant increase in nse levels during liver transplantations was deemed to might have been associated with causes other than neuronal damage, nse should not be evaluated as a marker of brain damage in these operations.


Eligibility criteria:
inclusion criteria: * score of 23 or above on the mini mental test (mmt) conducted in the preparation room prior to the operation, * no gastrointestinal bleeding in the last 1 month * no history of neuroactive drug use * consented for the study. exclusion criteria: * hepatic encephalopathy, * neurological disorder * psychiatric disorder,

Keywords: liver transplantation neuronal damage brain biochemical marker postoperative cognitive dysfunction
postoperative pain management in rhinoplasty

Conditions: Pain, Postoperative

Summary: the primary purpose of the study is to determine adequacy of postoperative pain control after nasal surgery in patients prescribed acetaminophen (325mg) + hydrocodone (5mg) compared to acetaminophen(325mg) + ibuprofen (200mg)for a period of 5 days after nasal surgery. to assess the degree of pain, the participants will score the intensity of their pain on a visual analog scale(vas)of 0-100points (0- no pain and 100- most severe pain), preoperatively and postoperatively (to be documented before each dose) for the duration of the prescribed medications . additionally, the study will also seek to track: 1. the total number of pills each patients consume from the prescribed 5 day regimen. 2. any associated side effects. 3. additional pain medications prescribed in case of inadequate pain control, postoperatively.

from this study, the investigators hope to learn the following: 1. is adequate postoperative pain management after nasal surgery achieved with opioid or non-opioid drugs? 2. if opioid drugs are required for adequate pain control postoperatively, is it possible to reduce the number of days the drugs are prescribed for? 3. what are the common side effect profiles of the included drugs? in light of the current opioid epidemic in the country, it is important the the physicians explore the utility of drugs other than opioids for adequate postoperative pain management. also, reducing the dosage and/or number of prescribed opioid drugs lessens the propensity for misuse of physician prescribed opioid medications.

Eligibility criteria:
inclusion criteria: * minimum age of 18 years * able to speak and understand english. * undergoing rhinoplasty for cosmetic purposes * undergoing rhinoplasty for treatment of nasal obstruction exclusion criteria: * less than 18 years of age * cannot speak and understand english * patients who have undergone nasal surgery in the past * patients not undergoing nasal surgery * women will be excluded if they are either pregnant or lactating as this population does not undergo nasal surgery at our center. * patients with any known allergies to the class of pain medications used in the study. please note: any person interested in this clinical trial should contact the facial plastic and reconstructive surgery clinic at (650) 736 - 3223 to schedule a consultation with dr. sam p. most to assess their eligibility for the trial. please note, enrolling in the clinical trial will not entitle the participant to a waiver of charges associated with undergoing nasal surgery.

Keywords: postoperative pain rhinoplasty
long-term follow-up study for patients previously treated with jcar015

Conditions: Acute Lymphoblastic Leukemia

Summary: this study will provide long-term follow-up for patients who have received treatment with jcar015 in a previous clinical trial. in this study, patients will be followed for up to 15 years after their last dose of jcar015 for evaluation of delayed adverse events, presence of persisting jcar015 vector sequences, and survival.


Eligibility criteria:
inclusion criteria: * patients who have received at least one dose of jcar015 in a previous treatment protocol. * patients who have provided informed consent for the long-term follow-up study prior to study participation. exclusion criteria: * none. all patients who have previously received jcar015 treatment are eligible for this long-term follow-up study.

Keywords: long-term follow-up chimeric antigen receptor (car) t cells jcar015
comparison of consolidation strategies for pediatric patients with acute myeloid leukemia

Conditions: AML; Pediatric AML

Summary: gatla 8-aml´07 trial is an multicenter phase iii dose-optimization trial for the treatment of acute myeloid leukemias in children and adolescents. patients are treated with a combination of intensive chemotherapy in combination with intrathecal-injection by cns and haematopoietic stem cell transplantation. the patients are stratified in a standard-group (sr) and a high risk-group (hr). sr was defined as fab (french-american-british) m1/m2 with auer rods; fab m4eo or favorable cytogenetics \[t(8;21)/aml1-eto or inv(16) or t(16;16) and/or cbfb/myh11)\]; bone marrow blasts ≤5% on day 15. hr was defined as all others. sr patients were reclassified to the hr group if flt3-itd positive. based on the experience of the bfm group, it was decided to randomly evaluate whether the six-drug conventional consolidation stage can be replaced with the use of a consolidation based by block therapy on drugs of proven efficacy in aml with the aim of reducing residual disease, and the toxicity of this stage. patients are randomized once the double induction is completed into those who will receive the conventional consolidation phase and those who will receive consolidation with the combination of high doses cytarabine and two different anthracyclines sequentially.

all patients in the trial, whether standard risk (sr) or high risk (hr), receive 2 induction courses: aie and ham and then are randomized to continue with the consolidation phase: a conventional consolidation (arm a) with 6 drugs vs 2 blocks of chemotherapy that are incorporated in this protocol (ai and ham) (arm b) and then an intensification phase with high doses of cytarabine and etoposide. the difference between the sr and ar groups is that the former don't continue with the maintenance phase, while those in hr receive 1 year of maintenance if they don't have a histoidentical family donor. sr patients according to cytogenetics and with \< 5% blasts in the bone marrow on day 15, haven´t indication for tchp in 1st cr. hr patients, with a histoidentical family donor, will be transplanted in the 1st. cr after the consolidation phases or the ai and ham blocks, according to the treatment arm that corresponded to them by randomization

Eligibility criteria:
inclusion criteria: * de novo aml * fab m0-m7 * primary myelosarcomas or acute mixed lineage leukemia / biphenotypic leukemia (predominantly myeloid). * written informed consent from patients, parents, or guardians was obtained at study entry in accordance with the declaration of helsinki exclusion criteria: * aml as secondary malignancy * children with down's syndrome * accompanying diseases which do not allow therapy according to the protocol * pre-treatment for more than 14 days with another intensive induction therapy * patients with apl * patients with myelodysplasia * patients with blast crisis of chronic myeloid leukemia * patients who die before starting treatment

Keywords: aml pediatric aml randomization
a comparison between titanium femoral stem and cobalt-chromium femoral stem in cemented hip arthroplasty

Conditions: Osteoarthritis

Summary: in this randomised study, the migration of a specific cemented titanium femoral stem will be compared with a similar cemented cobalt-chromium stem using roentgen stereogrammetric analysis (rsa). in addition, the periprosthetic bone mineral density (bmd) will be evaluated to point out any interference from the modulus of the stem investigated.


Eligibility criteria:
inclusion criteria: * primary osteoarthritis of the hip * spinal anesthesia * informed written consent exclusion criteria: * neuromuscular disease in the affected leg * vascular disease in the affected leg * fracture sequelae in the affected hip * weight over 100 kg * regular non-steroid anti-inflammatory drug (nsaid) intake in the postoperative period

Keywords: rsa osteoarthritis hip arthroplasty dexa titanium cobalt chromium bone cement
resource intervention to support equity (rise) in high-risk neuroblastoma

Conditions: Neuroblastoma; High-risk Neuroblastoma

Summary: the goal of this study is to test if the addition of a novel income-poverty targeted supportive care intervention (pediatric resource intervention to support equity \[pediatric rise\]) to usual supportive care for low-income children with high-risk neuroblastoma can improve parent- and child-centered outcomes. participants will be randomized to receive one of the following for 6-months: * usual supportive care alone or * usual supportive care plus pediatric rise

this is a randomized phase ii trial evaluating the addition of the rise supportive care equity intervention to usual supportive care for poverty-exposed children participants with newly diagnosed high-risk neuroblastoma. participants will be randomized into one of two groups: usual supportive care or pediatric rise plus usual supportive care. randomization means a participant is placed into a study group by chance. the research study procedures include screening for eligibility, in-person or virtual appointments, and surveys. participation in this research study is expected to last for about 6-months. it is expected that about 84 participants will take part in this research study.

Eligibility criteria:
inclusion criteria: patient cohort: the randomized phase ii multi-center rise intervention will be conducted among a population of poverty-exposed children with high-risk neuroblastoma. poverty will be a priori defined as parent-reported low-income (\<200% federal poverty level). children receiving treatment for cancer at study sites will serve as the study cohort, with parents/guardians as survey informants and intervention recipients on behalf of their minor children given that parents (not children) typically manage household finances. * patient newly diagnosed with high-risk neuroblastoma * patient has established care at study site and initiated cancer-directed therapy * patient has not yet initiated induction cycle 3 * patient aged 0-17 years at the time of consent * parent/guardian screened positive for self-reported low-income (\<200% federal poverty) \* * family primary residence in ma, pa, il, ca, wa, ct, ga, wi and oh * both patients co-enrolled on anbl2131 or those receiving standard of care therapy at their center are eligible to participate * patients of all languages are eligible to participate exclusion criteria: * foreign national family receiving care as an embassy-pay patient. * child or household member receiving ssi

Keywords: neuroblastoma high-risk neuroblastoma
glucoside- and rutinoside-rich crude material for relieving side effects of covid-19 vaccines

Conditions: Vaccine Adverse Reaction; Side-Effect

Summary: urgent vaccine development plus the characteristics of the coronavirus have caused the relatively more safety problems in covid-19 vaccines than other classic vaccines and unavoidably raises more concerns among those who accept or consider to be vaccinated. mulberry juice consists of a large amount of anthocyanin. the abnormally high interleukin-17a level is frequently seen in patients with inflammation status or diseases with inflammation features. some specific anthocyanins can reduce cyclooxygenase and nitrogen oxide, and the pharmacological effect of the major anthocyanin in mulberry juice imitates that of interleukin-17a antagonists. these features make mulberry juice a potential crude material for reducing inflammation and pain induced by covid-19 vaccinations. the investigators propose a randomized control trial to explore the dose-response effects of three different volumes of mulberry juice on the incidence and severity of covid-19 induced side effects. the findings should be helpful for nutrition supplementation in covid-19 vaccinations and may improve public coordination of covid-19 vaccinations.

since the outbreak of coronavirus disease-2019 (covid-19), the size of the infected population continues to expand, and the number of deaths due to the infection continues to climb. massive vaccination has become the most critical measure to control the pandemic. vaccination may cause side effects. urgent vaccine development plus the characteristics of the coronavirus have caused the relatively more safety problems in covid-19 vaccines than other classic vaccines and unavoidably raises more concerns among those who accept or consider to be vaccinated. mulberry juice consists of a large amount of anthocyanin. the abnormally high interleukin-17a level is frequently seen in patients with inflammation status or diseases with inflammation features. previous cell and animal studies have shown that some specific anthocyanins can reduce cyclooxygenase and nitrogen oxide, and the pharmacological effect of the major anthocyanin in mulberry juice imitates that of interleukin-17a antagonists. these features make mulberry juice a potential crude material for reducing inflammation and pain induced by covid-19 vaccinations. the investigators propose a randomized control trial investigating the dose-response effects of three different volumes of mulberry juice on the incidence and severity of covid-19 induced side effects and build up initial dose-response models for future reference in nutrition supplementation in covid-19 vaccinations and improve public coordination of covid-19 vaccinations.

Eligibility criteria:
inclusion criteria: * concious * mentally capable * can comunicate using mendalin or taiwanese dialet * agree to join the current trial exclusion criteria: * unable to read the google sheets * dysphagia * \> 65 years

Keywords: covid-19 vaccine adverse reaction side effect inflammation pain mulberry il-17
the curative effect of the length of the jejunum exclusion in grstric bypass surgery for type 2 diabetes

Conditions: Type 2 Diabetes; Obesity

Summary: the purpose of this study is to investigate the curative effect of the length of the jejunum exclusion in gastric surgry for t2dm and metabolic syndrome,and to draft scientific and reasonable operation parameters.

currently, there is a growing evidence supports the efficacy of roux-en-y gastric bypass for the treatment of type 2 diabetes mellitus. however,there still have a great controversy about the operation parameters. with randomized controlled trial, patients of bmi\>21kg/m2 with type 2 diabetes were randomly divided into two groups: short biliarypancreatic limb:50cm;long biliarypancreatic limb :100cm. the investigators followed-up 3,6,12,24 months of the change of bmi,fbg,hba1c,blood pressure,blood fat after surgery.

Eligibility criteria:
inclusion criteria: * aged 20-65 years old * history of diabetes is less than 15 years * fasting c-peptide≥1.6 * bmi≥21kg/m2； * ability to understand the nature of the procedure and willing to follow postoperative routine lifestyle and checkups exclusion criteria: * psychological and mental disorders * serious important organs such as heart and lung disease cannot be tolerated surgery * complex history of abdominal surgery in the abdominal cavity adhesion * pregnancy or lactation

Keywords: t2dm rygb rct
casopitant and zofran to prevent post operative nausea and vomiting in women

Conditions: Nausea and Vomiting, Postoperative; Postoperative Nausea and Vomiting

Summary: this study is being conducted to see if adding gw679769 (casopitant) to zofran will significantly decrease the number of patients who experience nausea and vomiting after surgery.


Eligibility criteria:
inclusion criteria: * history of ponv (postoperative nausea and vomiting) and/or motion sickness. * have not smoked for the last 6 months. * having certain abdominal, breast, thyroid or shoulder surgery. exclusion criteria: * pregnant or breastfeeding. * have certain pre-existing medical conditions or take certain medications.

Keywords: nk-1 antiemetics casopitant mesylate postoperative nausea and vomiting ondansetron hydrochloride 5ht3 zofran ponv
efficacy and safety study of jtt-654 in type 2 diabetic patients

Conditions: Type II Diabetes Mellitus

Summary: the purpose of this study is to evaluate the effect of jtt-654 on diabetes as well as the safety, tolerability and pharmacokinetics of jtt-654 in type 2 diabetic patients.


Eligibility criteria:
inclusion criteria: 1. have type 2 diabetes; 2. body mass index (bmi) of ≤ 45.0 kg/m2; 3. are either untreated with respect to hypoglycemic agents or are currently being treated with a stable dose of metformin alone. exclusion criteria: 1. females who are pregnant or breast-feeding; 2. known medical history or presence of type 1 diabetes or pancreatitis, acute metabolic diabetic complications, presence of unstable or rapidly progressing retinopathy, nephropathy or neuropathy; 3. acute coronary syndrome or uncontrolled hypertension; 4. does not meet all diet or previous/concomitant medication restrictions criteria, as described in the protocol.

Keywords: diabetes
management of acute pain in the emergency department

Conditions: Pain

Summary: oligoanalgesia1 has been widely recognized as an issue in emergency department.the purpose of our study is to assess the impact of the implementation of a computer-assisted support program to improve pain management in our ed.

inadequate pain management remains a major challenge for health care providers. despite extensive research on the mechanisms of acute pain, identification of factors leading to poor pain management and development of evidence-based strategies, the transfer of this knowledge into effective clinical practices has been surprisingly slow. oligoanalgesia1 has been widely recognized as an issue in emergency department (ed) patients. acute pain is reported by 60-80% of ed inpatients but is frequently undertreated. overall, an insufficient proportion of patients with acute pain receive any type of analgesia, and pain relief remains unsatisfactory. we showed that the implementation of guidelines improved pain management. however, rotation of the medical \& nursing staff leads to the forgetting of guidelines. the purpose of our study is to assess the impact of the implementation of a computer-assisted support program to improve pain management in our ed.

Eligibility criteria:
inclusion criteria: any patient admitted to our emergency department who is * age \> 16 years * pain lasting =\< 1 week or * no pain on admission but pain during the ed stay exclusion criteria: * life-threatening condition requiring immediate admission in the or or icu * no pain or pain lasting \>1 week * inability to give informed consent (intoxicated, psychiatric disorder, language problem, prisoner)

Keywords: pain pain measurement decision making, computer-assisted informatics